Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 107
- Registration Number
- NCT00377182
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00377481
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Phase 3
Completed
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 370
- Registration Number
- NCT00377637
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Phase 4
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 356
- Registration Number
- NCT00377234
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Phase 3
Completed
- Conditions
- Cytomegalovirus Infections
- Interventions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT00372229
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT00368368
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 127
- Registration Number
- NCT00366379
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT00365001
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
Phase 2
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00364832
A Study of Mircera in Anemic Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- Anemia
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00360347
© Copyright 2025. All Rights Reserved by MedPath